My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 140

    1.

    Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.

    Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA.

    Diabetes. 2008 Sep;57(9):2461-9. Epub 2008 May 28.PMID: 18511846 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis.

    Walcher D, Marx N.

    Semin Immunopathol. 2009 Jun;31(1):103-11. Epub 2009 Apr 5. Review.PMID: 19347338 [PubMed - indexed for MEDLINE]Related articles

    3.

    Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.

    Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K.

    J Mol Cell Cardiol. 2007 Oct;43(4):455-64. Epub 2007 Jul 21.PMID: 17761193 [PubMed - indexed for MEDLINE]Related articles

    4.

    Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.

    Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB.

    Circulation. 2007 Apr 24;115(16):2178-87. Epub 2007 Apr 9.PMID: 17420349 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

    Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA.

    Diabetologia. 2008 Sep;51(9):1731-40. Epub 2008 Jul 2.PMID: 18594792 [PubMed - indexed for MEDLINE]Related articles

    6.

    Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice.

    Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM.

    Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):905-10.PMID: 11397695 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.

    Chew P, Yuen DY, Koh P, Stefanovic N, Febbraio MA, Kola I, Cooper ME, de Haan JB.

    Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):823-30. Epub 2009 Mar 26.PMID: 19325139 [PubMed - indexed for MEDLINE]Related articles

    8.

    Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

    Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ.

    Diabetes. 2004 Jul;53(7):1813-23. Erratum in: Diabetes. 2006 Mar;55(3):862. Thorpe, Susan M [corrected to Thorpe, Susan R]. PMID: 15220206 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.

    Schmidt AM, Yan SD, Wautier JL, Stern D.

    Circ Res. 1999 Mar 19;84(5):489-97. Review.PMID: 10082470 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.

    Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D.

    J Clin Invest. 1995 Sep;96(3):1395-403.PMID: 7544803 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.

    Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y.

    Nephrol Dial Transplant. 2004 Dec;19(12):3012-20.PMID: 15574998 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.

    Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM.

    J Clin Invest. 2008 Jan;118(1):183-94.PMID: 18079965 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.

    Gao X, Zhang H, Schmidt AM, Zhang C.

    Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H491-8. Epub 2008 Jun 6.PMID: 18539754 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.

    Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

    Diabetologia. 2006 Apr;49(4):766-74. Epub 2006 Feb 4.PMID: 16463048 [PubMed - indexed for MEDLINE]Related articles

    15.

    Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.

    Ding H, Hashem M, Triggle C.

    Eur J Pharmacol. 2007 Apr 30;561(1-3):121-8. Epub 2007 Jan 20.PMID: 17292348 [PubMed - indexed for MEDLINE]Related articles

    16.

    Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.

    Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min LJ, Mogi M, Horiuchi M.

    Circulation. 2005 Sep 13;112(11):1636-43. Epub 2005 Sep 6.PMID: 16145000 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.

    Yamagishi S, Matsui T, Nakamura K.

    Med Hypotheses. 2008 Nov;71(5):749-51. Epub 2008 Aug 16.PMID: 18710793 [PubMed - indexed for MEDLINE]Related articles

    18.

    Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study.

    Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R.

    Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1266-71. Epub 2004 May 13.PMID: 15142859 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis.

    Hodgkinson CP, Laxton RC, Patel K, Ye S.

    Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2275-81. Epub 2008 Sep 25.PMID: 18818414 [PubMed - indexed for MEDLINE]Related articles

    20.

    Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice.

    Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA, Dellsperger KC, Weintraub NL.

    Circulation. 2006 Aug 1;114(5):404-13. Epub 2006 Jul 24.PMID: 16864727 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity